Adeka (4401) Q4 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2026 earnings summary
14 May, 2026Executive summary
Net sales, operating profit, ordinary profit, and profit attributable to owners of parent all reached record highs for the year ended March 31, 2026, despite a challenging global environment with uncertainties in resource prices and geopolitical tensions.
The company achieved 2.3% year-over-year growth in net sales and 1.5% growth in operating profit, with profit attributable to owners of parent up 11.4% year-over-year.
Financial highlights
Net sales: ¥416,563 million (+2.3% YoY); Operating profit: ¥41,614 million (+1.5% YoY); Ordinary profit: ¥42,772 million (+8.7% YoY); Profit attributable to owners of parent: ¥27,866 million (+11.4% YoY).
Basic earnings per share: ¥277.95 (up from ¥245.55 YoY).
Comprehensive income: ¥47,507 million (+87.3% YoY).
Cash flows from operating activities: ¥40,612 million (down 12.2% YoY); investing activities: ¥-30,078 million; financing activities: ¥-35,301 million.
Cash and cash equivalents at year-end: ¥87,884 million (down 18.5% YoY).
Outlook and guidance
For the fiscal year ending March 31, 2027, net sales are forecast at ¥453,000 million (+8.7% YoY), operating profit at ¥46,800 million (+12.5% YoY), and profit attributable to owners of parent at ¥28,800 million (+3.4% YoY).
Annual dividend forecast for FY2027 is ¥120 per share, up from ¥112 per share in FY2026.
The company expects continued growth in semiconductor, automotive, food, and life science sectors, but notes ongoing risks from resource prices and geopolitical instability.
Latest events from Adeka
- Profit rose on strong Life Science and Environmental Materials, offsetting Chemicals weakness.4401
Q3 202627 Apr 2026 - Profit and sales rose, led by Life Science, with stable outlook and higher dividend forecast.4401
Q1 202610 Mar 2026 - Life Science strength drove profit growth, offsetting Chemicals and Food Products weakness.4401
Q2 202610 Mar 2026 - Profits and sales grew, led by Chemicals and Food Products, with raised outlook and Life Science loss.4401
Q1 202510 Mar 2026 - Strategic investments and innovation in semiconductor materials target rapid global growth.4401
Investor presentation10 Mar 2026 - 3Q FY2024 saw higher sales and profits, driven by Chemicals and global expansion.4401
Q3 202510 Mar 2026 - Strong 1H FY2024 results and Chemicals growth led to higher guidance and dividend forecasts.4401
Q2 202510 Mar 2026 - Record sales and profit growth driven by Chemicals, with continued expansion and higher dividends forecast.4401
Q4 202510 Mar 2026